Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

被引：0
|
作者：
van Wesemael, Tineke [1 ]
Borgers, Jessica [2 ]
Gelderman, Kyra [3 ]
Verdegaal, Els [4 ]
Korse, C. M. [5 ]
Welters, M. J. P. [6 ]
Kapiteijn, Ellen [7 ]
van Houdt, W. J. [2 ]
van der Burg, Sjoerd [6 ]
Toes, Rene [1 ]
Thienen, J. V. [2 ]
Haanen, John [2 ]
van der Woude, Diane [1 ]
机构：
[1] Leiden Univ Med Ctr, Leiden, Netherlands
[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Sanquin Diagnost Serv, Amsterdam, Netherlands
[4] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Netherlands Canc Inst, Dept Lab Med, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[6] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ Med Ctr, Dept Med Oncol, Leiden, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2510
引用
收藏
页码：4977 / 4979
页数：3
相关论文
共 50 条
  • [41] Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
    Delaney, Nicolas
    Michot, Jean-Marie
    Comont, Thibault
    Kramkimel, Nora
    Lazarovici, Julien
    Dupont, Romain
    Champiat, Stephane
    Chahine, Claude
    Robert, Caroline
    Herbaux, Charles
    Besse, Benjamin
    Guillemin, Aude
    Mateus, Christine
    Pautier, Patricia
    Saiag, Purippe
    Madonna, Enmauela
    Maerevoet, Marie
    Bout, Jeao-Christophe
    Leduc, Charlotte
    Biscay, Pascal
    Quere, Gilles
    Nardin, Charlee
    Ebbo, Mikael
    Albiges, Laurence
    Marret, Gregoire
    Levrat, Virginie
    Dujon, Cecile
    Vargaftig, Jacques
    Laghouati, Salim
    Croisille, Loure
    Voisin, Anne-Laure
    Godeau, Bertrand
    Massard, Christophe
    Ribrag, Vincent
    Marabelle, Aurellen
    Michel, Marc
    Lambotte, Olivier
    LANCET HAEMATOLOGY, 2019, 6 (01): : E48 - E57
  • [42] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Baxi, Shrujal
    Yang, Annie
    Gennarelli, Renee L.
    Khan, Niloufer
    Wang, Ziwei
    Boyce, Lindsay
    Korenstein, Deborah
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [43] Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy
    Narvaez, J.
    Juarez-Lopez, P.
    LLuch, J.
    Narvaez, J. A.
    Palmero, R.
    Garcia del Muro, X.
    Nolla, J. M.
    Domingo-Domenech, E.
    AUTOIMMUNITY REVIEWS, 2018, 17 (10) : 1040 - 1045
  • [44] Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
    Rogado, Jacobo
    Romero-Laorden, Nuria
    Miguel Sanchez-Torres, Jose
    Maria Ramos-Levi, Ana
    Pacheco-Barcia, Vilma
    Isabel Ballesteros, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido, Ana
    Serra Lopez-Matencio, Jose Maria
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantzazu
    Mondejar, Rebeca
    Colomer, Ramon
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [45] Diet-induced obesity predisposes anti-PD-1 antibody-treated mice to imiquimod-mediated psoriasiform dermatitis: implications for immune-related adverse events in cancer patients treated with anti-PD-1
    Yu, S.
    Wu, X.
    Shi, Z.
    Huynh, M.
    Hwang, S. T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S4 - S4
  • [46] Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
    Bomze, David
    Ali, Omar Hasan
    Bate, Andrew
    Flatz, Lukas
    JAMA ONCOLOGY, 2019, 5 (11) : 1633 - 1635
  • [47] Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
    Huang, Yiqing
    Soon, Yu Yang
    Aminkeng, Folefac
    Tay, Sen Hee
    Ang, Yvonne
    Kee, Adrian C. L.
    Goh, Boon Cher
    Wong, Alvin S. C.
    Soo, Ross A.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 636 - 644
  • [48] Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer
    Xue, Dinglong
    Li, Ning
    Yang, Jiaxin
    Men, Kaiya
    Li, Lijun
    Jiang, Hao
    Zhao, Xu
    Zhang, Shuai
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [50] Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy
    Duma, N.
    Azzouqa, A-G.
    Yadav, S.
    Hoversten, K.
    Reed, C.
    Sitek, A. N.
    Lou, Y.
    Molina, J.
    Halfdanarson, T.
    Leventakos, K.
    Joseph, R. W.
    Manochakian, R.
    Dronca, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 432 - 432
12345